{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:51:40Z","timestamp":1793832700238,"version":"4.6.1"},"reference-count":32,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2018,2,18]],"date-time":"2018-02-18T00:00:00Z","timestamp":1518912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>\n                    Background: Previous meta-analyses suggest that users of proton pump inhibitors (PPIs) have a higher risk of developing enteric infections compared with nonusers. These previous meta-analyses have considerable heterogeneity, and it is not clear whether the effect of PPIs is different for different types of microorganisms. Objective: The aim of this study is to update previous meta-analyses, concentrating on enteric infection in community settings and exploring potential sources of heterogeneity. Methods: A systematic search was conducted on electronic databases (all available years until November 2017). PubMed, EMBASE, Cochrane, and Web of Science were searched using specific keywords related to PPI therapy and community-acquired enteric infection. Eligible studies were selected based on prespecified criteria. Results: A total of 9 observational studies evaluating community-acquired enteric infection were eligible, including 12 separate analyses. The meta-analysis showed that PPI users have an increased risk of developing community-acquired enteric infection (pooled odds ratio [OR] = 4.28; 95% CI = 3.01-6.08). There was significant heterogeneity between the studies ( I\n                    <jats:sup>2<\/jats:sup>\n                    = 85%; P &lt; 0.001), which was partly explained by type of microorganism. The strength of the association was similar for Salmonella (pooled OR = 4.84; 95% CI = 2.75-8.54; I\n                    <jats:sup>2<\/jats:sup>\n                    = 58.7%; P = 0.064) and Campylobacter (pooled OR = 5.09; 95% CI = 3-8.64; I\n                    <jats:sup>2<\/jats:sup>\n                    = 81%; P &lt; 0.001) but lower for studies that combined all bacteria (pooled OR = 2.42; 95% CI = 0.96-6.14; I\n                    <jats:sup>2<\/jats:sup>\n                    = 94.3%; P &lt; 0.001). Conclusion: PPI users have an increased risk of developing community-acquired enteric infections compared with nonusers. The heterogeneity was partially explained by type of microorganism; the association is stronger for Salmonella and Campylobacter than for all bacteria combined.\n                  <\/jats:p>","DOI":"10.1177\/1060028018760569","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T02:24:42Z","timestamp":1519007082000},"page":"613-622","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":61,"title":["The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis"],"prefix":"10.1177","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-0232","authenticated-orcid":false,"given":"Radwan A.","family":"Hafiz","sequence":"first","affiliation":[{"name":"Drug sector, Saudi Food and Drug Authority-Riyadh, Kingdom of Saudi Arabia"},{"name":"University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia","family":"Wong","sequence":"additional","affiliation":[{"name":"University of Queensland, Brisbane, Australia"},{"name":"Tan Tock Seng Hospital-Novena, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Paynter","sequence":"additional","affiliation":[{"name":"University of Queensland, Brisbane, Australia"},{"name":"Curtin University, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"David","sequence":"additional","affiliation":[{"name":"University of Queensland, Brisbane, Australia"},{"name":"University of Newcastle, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeske","family":"Peeters","sequence":"additional","affiliation":[{"name":"University of Queensland, Brisbane, Australia"},{"name":"Global Brain Health Institute, University of California San Francisco & Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,2,18]]},"reference":[{"key":"bibr1-1060028018760569","unstructured":"Astrazeneca. AstraZeneca annual report and Form 20-F information 2016: financial review. https:\/\/www.astrazeneca.com\/investor-relations\/annual-reports.html. Accessed January 21, 2018."},{"key":"bibr2-1060028018760569","volume-title":"Pharmacology","volume":"3","author":"Howland RD","year":"2006"},{"key":"bibr3-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1053\/bega.2001.0184"},{"key":"bibr4-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1136\/gut.42.2.266"},{"key":"bibr5-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04874.x"},{"key":"bibr6-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050836"},{"key":"bibr7-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01275.x"},{"key":"bibr8-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"bibr9-1060028018760569","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed September 16, 2015."},{"key":"bibr10-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"bibr11-1060028018760569","volume-title":"Meta-analysis in Stata: An Updated Collection From the Stata Journal","author":"Jonathan AC","year":"2009"},{"key":"bibr12-1060028018760569","unstructured":"Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions: Meta-regression http:\/\/handbook.cochrane.org\/chapter_9\/9_6_4_meta_regression.htm. Accessed April 3, 2016."},{"key":"bibr13-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.010"},{"key":"bibr14-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"bibr15-1060028018760569","volume-title":"Stata Statistical Software: Release 12","year":"2011"},{"key":"bibr16-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.30"},{"key":"bibr17-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1089\/fpd.2016.2170"},{"key":"bibr18-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13205"},{"key":"bibr19-1060028018760569","first-page":"S230","volume":"31","author":"Chahal KS","year":"2016","journal-title":"J Gen Intern Med"},{"key":"bibr20-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1017\/S095026881000052X"},{"key":"bibr21-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268805005406"},{"key":"bibr22-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199709000-00016"},{"key":"bibr23-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.09.010"},{"key":"bibr24-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7028.414"},{"key":"bibr25-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268897008224"},{"key":"bibr26-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268815002332"},{"key":"bibr27-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-016-0136-8"},{"key":"bibr28-1060028018760569","volume-title":"An Introduction to Medical Statistics","author":"Bland M.","year":"2009","edition":"3"},{"key":"bibr29-1060028018760569","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.64.10.3882-3886.1998"},{"key":"bibr30-1060028018760569","unstructured":"Foodsafety.gov. Campylobacter. https:\/\/www.foodsafety.gov\/poisoning\/causes\/bacteriaviruses\/campylobacter\/index.html. Accessed January 11, 2018."},{"key":"bibr31-1060028018760569","unstructured":"Foodsafety.gov. Salmonella. https:\/\/www.foodsafety.gov\/poisoning\/causes\/bacteriaviruses\/salmonella\/index.html. Accessed January 11, 2018."},{"key":"bibr32-1060028018760569","volume-title":"Applied Therapeutics: The Clinical Use of Drugs","volume":"10","author":"Koda-Kimble MA","year":"2013"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018760569","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028018760569","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018760569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:19Z","timestamp":1777374859000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028018760569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,18]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1177\/1060028018760569"],"URL":"https:\/\/doi.org\/10.1177\/1060028018760569","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,18]]}}}